<u>EBMT</u> <u>Annual report</u> <u>2021</u>



ScienceEducationPatient Care & Advocacy

Our SocietyOur Mission, Vision & ValuesEquality, Diversity & InclusionEBMT Membership 2021Organisational Structure 2021Financial Highlights 2021EBMT Partners

Breadcrumb

1. <u>Home</u>

Entity Print



Régis Peffaut de Latour SAAWP Chair France

Major achievements

Top level publication and initiation of the RACE-2 trial:

1. RACE trial comparing standard immunosuppressive therapy (ATG+CsA) plus Eltrombopag vs Standard IST alone in patients with severe aplastic anemia (SAA) has been accepted for publication in the NEJM on October 14th 2021. This EBMT study, supported financially by Novartis, Pfizer and Alexion, demonstrated that Eltrombopag at the top of standard hATG+CSA was associated with a better and quicker response at 3 and 6 months. At 2 years, event free survival was significantly higher for patients receiving first line the experimental treatment. Horse ATG+CSA+Eltrombopag is now the standard of care for adult patients with SAA. We acknowledge the Clinical Trial Office (CTO) of the EBMT, together with all RACE investigators and nurses for their outstanding work, as well as patients who have accepted to participate to this trial.

2. The RACE-2 trial is ready in 2021. This retrospective study will assess the longterm follow-up of patients included in RACE which is of outstanding importance to evaluate the long-term safety of the use of Eltrombopag first line in patients with SAA. The trial will begin early 2022.

Principal research studies

Haploidentical stem cell transplantation for congenital bone marrow failure Study type **Retrospective Studies** Diseases Bone marrow failure Group Severe Aplastic Anaemia Working Party (SAAWP) Type of treatment Allogeneic - Haploidentical Principal investigator Dr. Stefano Giardino Clonal evolution in acquired aplastic anemia Study type **Retrospective Studies** Diseases Bone marrow failure Group Severe Aplastic Anaemia Working Party (SAAWP) Type of treatment Allogeneic

Principal investigator Pedro de Lima Prata Androgens in bone marrow failure disorders Study type **Retrospective Studies** Diseases Bone marrow failure Group Severe Aplastic Anaemia Working Party (SAAWP) Type of treatment - None -Principal investigator Simona Pagliuca, Austin Kulasekararaj GvHD and relapse free survival after allogeneic transplantation for idiopathic severe aplastic anemia Study type **Retrospective Studies** Diseases Bone marrow failure Group Severe Aplastic Anaemia Working Party (SAAWP) Type of treatment Allogeneic Principal investigator **Raynier Devillier**


Key publications

2021 Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia Group Severe Aplastic Anaemia Working Party (SAAWP) 1st listed author Régis Peffault de Latour Journal N Engl J Med. 2021

Upfront unrelated donor Hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: a retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation Group Severe Aplastic Anaemia Working Party (SAAWP) 1st listed author Audrey Françoise Petit Journal Am J Hematol. 2021 Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: results from the Severe Aplastic Anemia Working Party of the EBMT Group Severe Aplastic Anaemia Working Party (SAAWP) 1st listed author Josune Zubicaray Journal Am J Hematol. 2021 Stem Cell Transplantation for Diamond-Blackfan Anemia. A Retrospective Study on Behalf of the Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT) Group Severe Aplastic Anaemia Working Party (SAAWP) 1st listed author Maurizio Miano Journal Transplant Cell Ther. 2021 Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study Group Severe Aplastic Anaemia Working Party (SAAWP) 1st listed author **Pierre-Edouard Debureaux** Journal Bone Marrow Transplant.

See the full list of the SAAWP 2021 publications





2019 2020 2021

Oral presentations	8	4	8
Poster presentations	1	6	0
Educational events	2	4	3